15 February 2025 in Archives of Dermatological Research
11 September 2026 in JMIR Dermatology
Background: Maldistribution of providers, differences in insurance coverage and acceptance, and underrepresentation of underserved patient populations in dermatology all affect patient access to dermatology services. Few studies have evaluated institutional models to address these pervasive gaps. Objective: The aim of this study was to evaluate one academic institution’s efforts to comprehensively expand access to dermatology services. Methods: A retrospective analysis was performed using data from the University of Utah Health (UUH) Department of Dermatology’s outreach initiatives compared with general dermatology ambulatory clinics on UUH’s main campus in Salt Lake City, Utah, over 3 years. Descriptive statistics were reported for patient demographics, insurance coverage, and diagnoses at the encounter level. Statistical methods assessed differences between clinic types. Outreach initiatives were categorized by delivery method: rural in-person clinics, urban in-person charity care clinics, live video teledermatology in rural and incarcerated settings, and asynchronous eConsults (store-and-forward teledermatology). Results: Outreach initiatives served 2283 distinct patients in 3471 encounters. The general dermatology clinics at UUH served 207,493 patients in 1,141,280 encounters. Overall, UUH outreach initiatives served a more diverse, younger, and Medicaid-insured patient population with a higher prevalence of inflammatory/autoimmune conditions than its general ambulatory dermatology clinics. eConsult and charity care clinics more commonly served patients younger than 65 years of age, and eConsults in particular served a more racially and ethnically diverse patient population compared with the general dermatology clinics. Conclusions: This study confirms that UUH Dermatology’s efforts to enhance health care access effectively reach targeted underserved patient populations that are underrepresented at UUH’s general dermatology clinics.
16 June 2026 in Clinical Case Reports
Symmetric, purpuric hand nodules and macroglossia prompted skin biopsy revealing immunoglobulin light chain amyloidosis, leading to the diagnosis of multiple myeloma. Early detection of typical and atypical cutaneous amyloidosis presentations, such as this patient, is imperative for clinicians to initiate timely hematologic workup and treatment to improve patient outcomes and survival.
24 December 2025 in Advanced Neurology
Pediatric primary central nervous system (CNS) melanoma is a rare and aggressive malignancy, often arising in association with neurocutaneous melanosis but also reported in sporadic cases. Children typically present with signs of increased intracranial pressure, seizures, or focal neurological deficits. Median age at diagnosis is 2.8–3.7 years, that is, under four years, although cases spanning infancy to early adolescence have been reported. Median survival rarely exceeds one year despite multimodal therapy. Melanogenesis may directly influence tumor behavior, as intermediates generate oxidative stress and contribute to radioresistance and variable immunotherapy response. Pediatric CNS melanomas frequently harbor activating mutations in GNAQ, GNA11, or NRAS, which drive mitogen-activated protein kinase and phosphoinositide 3-kinase–AKT signaling to promote proliferation and confer resistance to apoptosis. Additional alterations, such as CDKN2A and TP53 loss, may be linked to accelerated progression. Unlike cutaneous melanoma, BRAF mutations are uncommon. Maximal surgical resection remains the cornerstone of therapy, offering the greatest survival benefit. Adjuvant radiotherapy or chemoradiation provides limited efficacy due to the intrinsic radioresistance of melanoma cells and the restricted delivery of therapeutic agents across the blood–brain barrier (BBB). Among chemotherapies, temozolomide has modest CNS activity, whereas checkpoint inhibitors and targeted agents have shown only transient responses in pediatric case reports. These therapeutic challenges underscore the urgent need for novel strategies that can overcome BBB-related barriers to drug delivery and melanin-mediated resistance. Advances in molecular profiling and targeted drug development, coupled with education for early diagnosis, may improve survival in patients with this aggressive disease.
27 November 2025 in The Journal for Nurse Practitioners